Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance - PubMed (original) (raw)
Review
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance
Nuzhat Ahmed et al. J Cell Biochem. 2013 Jan.
Abstract
Chemotherapy with platinum and taxanes is the first line of treatment for all epithelial ovarian cancer (EOC) patients after debulking surgery. Even though the treatment is initially effective in 80% of patients, recurrent cancer is inevitable in the vast majority of cases. Emerging evidence suggests that some tumor cells can survive chemotherapy by activating the self-renewal pathways resulting in tumor progression and clinical recurrence. These defined population of cells commonly termed as "cancer stem cells" (CSC) may generate the bulk of the tumor by using differentiating pathways. These cells have been shown to be resistant to chemotherapy and, to have enhanced tumor initiating abilities, suggesting CSCs as potential targets for treatment. Recent studies have introduced a new paradigm in ovarian carcinogenesis which proposes in situ carcinoma at the fimbrial end of the fallopian tube to generate high-grade serous ovarian carcinomas, in contrast to ovarian cortical inclusion cysts (CIC) which produce borderline and low grade serous, mucinous, endometrioid, and clear cell carcinomas. This review summarizes recent advances in our understanding of the cellular origin of EOC and the molecular mechanisms defining the basis of CSC in EOC progression and chemoresistance. Using a model ovarian cancer cell line, we highlight the role of CSC in response to chemotherapy, and relate how CSCs may impact on chemoresistance and ultimately recurrence. We also propose the molecular targeting of CSCs and suggest ways that may improve the efficacy of current chemotherapeutic regimens needed for the management of this disease.
Copyright © 2012 Wiley Periodicals, Inc.
Similar articles
- [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN, Zeng LX, Li YH, Liu YZ, Wu JY, Li L, Wang Q. Mao YN, et al. Zhonghua Fu Chan Ke Za Zhi. 2017 Oct 25;52(10):687-696. doi: 10.3760/cma.j.issn.0529-567X.2017.10.008. Zhonghua Fu Chan Ke Za Zhi. 2017. PMID: 29060967 Chinese. - Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.
Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H, Kunisada T, Yano M, Kuji S, Hirashima Y, Arakawa A, Nishio S, Ushijima K, Ito K, Itani Y, Morishige K. Mizuno T, et al. Gynecol Oncol. 2015 May;137(2):299-305. doi: 10.1016/j.ygyno.2014.12.005. Epub 2014 Dec 23. Gynecol Oncol. 2015. PMID: 25541259 - Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I, Seidal T. Skírnisdóttir I, et al. Int J Gynecol Cancer. 2011 Aug;21(6):1024-31. doi: 10.1097/IGC.0b013e31821dc906. Int J Gynecol Cancer. 2011. PMID: 21792012 - Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG. McCluggage WG. Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Pathology. 2011. PMID: 21716157 Review. - Ovarian serous carcinogenesis from tubal secretory cells.
Zhang W, Wei L, Li L, Yang B, Kong B, Yao G, Zheng W. Zhang W, et al. Histol Histopathol. 2015 Nov;30(11):1295-302. doi: 10.14670/HH-11-645. Epub 2015 Jul 15. Histol Histopathol. 2015. PMID: 26174492 Review.
Cited by
- STAU1-mediated CNBP mRNA degradation by LINC00665 alters stem cell characteristics in ovarian cancer.
Liu X, Chen Y, Li Y, Bai J, Zeng Z, Wang M, Dong Y, Zhou Y. Liu X, et al. Biol Direct. 2024 Jul 30;19(1):59. doi: 10.1186/s13062-024-00506-w. Biol Direct. 2024. PMID: 39080743 Free PMC article. - Differentially expression and function of circular RNAs in ovarian cancer stem cells.
Sohn EJ. Sohn EJ. J Ovarian Res. 2022 Aug 17;15(1):97. doi: 10.1186/s13048-022-01014-z. J Ovarian Res. 2022. PMID: 35978436 Free PMC article. - New developments in the treatment of ovarian cancer--future perspectives.
Lopez J, Banerjee S, Kaye SB. Lopez J, et al. Ann Oncol. 2013 Dec;24 Suppl 10(Suppl 10):x69-x76. doi: 10.1093/annonc/mdt475. Ann Oncol. 2013. PMID: 24265409 Free PMC article. Review. - Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell.
Lee HG, Shin SJ, Chung HW, Kwon SH, Cha SD, Lee JE, Cho CH. Lee HG, et al. J Gynecol Oncol. 2017 Mar;28(2):e14. doi: 10.3802/jgo.2017.28.e14. Epub 2016 Nov 14. J Gynecol Oncol. 2017. PMID: 27894167 Free PMC article. - STAT3 signaling in ovarian cancer: a potential therapeutic target.
Liang R, Chen X, Chen L, Wan F, Chen K, Sun Y, Zhu X. Liang R, et al. J Cancer. 2020 Jan 1;11(4):837-848. doi: 10.7150/jca.35011. eCollection 2020. J Cancer. 2020. PMID: 31949487 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous